Estonian company developing innovative genetics tests for cancer risk assessment, based on polygenic risk score technology is looking for distributors in various healthcare markets.

[ad_1]
A health-tech company based in Estonia has developed genetic tests (CE-marked) for breast, prostate, colorectal cancer, and skin melanoma based on polygenic risk score (PRS) technology. The tests assess patient’s personal cancer risks and give clinical recommendations for further treatment. All tests are intended for use in the healthcare. The company wants to expand in Scandinavia and Central Europe countries and is looking for distributors in various healthcare markets.

[ad_2]